Best Recombinant Proteins CDMOs in Japan
· updated as new inspection, certificate, and trial data enters the platform
1
CDMOs tracked
1
Fully scored
1
With FDA records
2
FDA inspections
23
EMA/MHRA GMP certs
Recombinant protein CDMOs make therapeutic proteins, enzymes, and growth factors using microbial (E. coli, yeast) or mammalian (CHO) expression. Choice of host turns on post-translational modification needs, scale economics, and downstream-purification complexity.
Selecting a recombinant protein CDMO turns on host-system experience, validated bioreactor scale, downstream purification and analytics, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 1 NAI (no action), 1 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (18), Germany (3), United States (2), Italy (2).
Last updated 2026-07-06. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 2 insp · 23 GMP | Available | 2 programs |
What to evaluate in a Recombinant Proteins CDMO
Expression host & scale
Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target.
Purification & analytics
Downstream complexity (multiple chromatography steps, refolding for E. coli) drives cost and timeline. Ask about the orthogonal analytics package — purity, identity, potency.
Regulatory readiness
Clean FDA 483 history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & commercial readiness
For programs heading to BLA, evaluate validated commercial scale and any approved-product track record.
How does Japan's regenerative medicine regulatory framework affect cell and gene therapy CDMOs?
Japan operates one of the most developed advanced-therapy regulatory frameworks globally, distinguishing between three product classes with tailored requirements: regenerative medical products, cellular/tissue-based products, and gene therapy products. The framework's conditional and time-limited early approval pathway (introduced 2014, revised 2024) has accelerated advanced-therapy commercialization in Japan compared to most other markets. For CDMOs, this means Japanese advanced-therapy manufacturers have accumulated real experience with regulatory-supported early commercial supply — a signal that materially differs from the more restrictive US and EU pathways. Cross-reference with cell therapy, AAV, and cell & gene therapy umbrella pages for Japanese CDMO capability at the modality level.
PMDA regulatory posture — how does it compare to FDA and EMA?
PMDA GMP is generally regarded as tier-equivalent to FDA and EMA — inspections are rigorous, the framework is well-documented, and PMDA participates in the PIC/S mutual-recognition framework alongside EMA and other major regulators. For Japanese-manufactured product supplying US or EU markets, the qualifying signal is FDA or EMA inspection posture on the specific facility (not just PMDA certification), because FDA and EMA conduct their own facility inspections regardless of PMDA status. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly. Japanese CDMOs supplying global markets typically hold cross-jurisdictional certification.
Which Japanese CDMOs supply US and European markets?
The Japanese CDMOs with US and EU inspection posture typically operate global site networks or maintain FDA-inspected export facilities. Cross-check with the US region ranking and Europe region ranking to identify Japanese CDMOs appearing across regions — these have demonstrated multi-jurisdictional inspection posture. Individual profile pages surface facility-level detail on which specific Japanese sites carry which regulatory certifications.
Recombinant Proteins CDMOs — Frequently Asked Questions
Who are the top Recombinant Proteins CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Recombinant Proteins CDMOs include AGC Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Recombinant Proteins CDMOs have FDA inspection records?
CDMO Signal tracks 1 Recombinant Proteins CDMO with FDA inspection records and 23 EMA/MHRA GMP certificates across the group.
What should I look for in a recombinant protein CDMO?
Confirm expression-host experience for your target (microbial vs mammalian), validated bioreactor scale, a strong downstream-purification platform, qualified analytics, and a clean FDA and EMA/MHRA record.
How is a recombinant protein CDMO different from a mAb CDMO?
There's significant overlap — mAbs are recombinant proteins. But mAb CDMOs are typically optimized for CHO-based platform processes, while general recombinant protein CDMOs handle a wider range of hosts and non-mAb formats (enzymes, growth factors, complex non-glycoproteins).
Related modalities